StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN): "if results are replicated in US, could lead to preferential prescribing"
March 9, 2026 9:59 AM
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $880.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
